UT-MYHERITAGE
MyHeritage , den førende globale tjeneste til at opdage din fortid og tage kontrol over din fremtid, annoncerede i dag udgivelsen Deep Nostalgia™ , en ny funktion, der animerer ansigterne i stillbilleder. Deep Nostalgia™ giver slægtshistorien et helt nyt perspektiv ved at producere en realistisk skildring af, hvordan en person kunne have bevæget sig og set ud, hvis de blev fanget på video. MyHeritage er det eneste firma, der tilbyder en komplet pakke af funktioner til farvelægning, gendannelse, forbedring og nu animering af historiske fotos.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20210225005924/da/
Teknologien til animering af ansigterne på fotos blev licenseret af MyHeritage fra D-ID , et firma, der specialiserer sig i videogenskabelse ved hjælp af 'deep learning'. Deep Nostalgia™ bruger flere forindspillede driver-videoer udarbejdet af MyHeritage, som styrer bevægelserne i animationen og består af sekvenser af ægte menneskelige bevægelser. En foretrukken driver, baseret på dets retning, vælges automatisk for hvert ansigt, og anvendes derefter problemfrit på fotoet. Resultatet er en kort videoanimation i høj kvalitet af et ansigt, der kan smile, blinke og bevæge sig. For at opnå optimale resultater forbedres billederne inden animationen ved hjælp af MyHeritage Photo Enhancer , som giver slørede ansigter med lav opløsning fokus og øger deres opløsning.
Deep Nostalgia™ er det nyeste AI-baserede fotoværktøj på MyHeritage, og kommer i kølvandet på to meget roste funktioner, som virksomheden udgav sidste år, MyHeritage Photo Enhancer og MyHeritage In Color™ , der farvelægger sorte-hvide fotos og for nylig blev udvidet til også at gendanne farverne i falmede farvefotos. Disse funktioner er blevet virale og brugt over 30 millioner gange. MyHeritage fortsætter med at bygge på dette momentum ved at tilføje nye banebrydende værktøjer til historiske fotos, der inspirerer til en ny forståelse for slægtshistorie og nostalgiske familiefotos.
"Du oplever et 'wow-øjeblik', når du ser et værdsat familiefoto komme til live med Deep Nostalgia™”, sagde Gilad Japhet, grundlægger og administrerende direktør for MyHeritage. "At se vores elskede forfædres ansigter komme til live i en videosimulering giver os mulighed for at forestille os, hvordan de kunne have været i virkeligheden, og giver en helt ny måde at blive forbundet til vores slægtshistorie."
"Denne nye produktintegration er et spændende samarbejde mellem to innovative virksomheder," sagde Gil Perry, medstifter og administrerende direktør for D-ID. "Vi er begejstrede for, at vores teknologi vil være tilgængelig for millioner af mennesker på MyHeritage, og vi håber, at mange af dem vil nyde virkningen af videogenskabelse af historiske fotos."
Integration i MyHeritage-platformen
Deep Nostalgia™ er en freemium-funktion på MyHeritage. Brugere kan animere flere fotos gratis, uanset antallet af ansigter på billedet. Ud over det kræver fortsat brug et abonnement. Videoanimationen kan let deles med familie og venner på Facebook, Twitter, WhatsApp og andre sociale medier.
Om MyHeritage
MyHeritage er den førende globale platform til at opdage og udforske slægtshistorie. Med milliarder af historiske optegnelser og slægttræsprofiler og med sofistikerede matching-teknologier på tværs af alle dens aktiver, giver MyHeritage brugere mulighed for at opdage deres fortid og tage kontrol over deres fremtid. MyHeritage DNA er en af verdens største DNA-databaser med 4,7 millioner kunder. MyHeritage er den mest populære tjeneste for DNA-test og slægtsforskning i Europa. Siden 2020 er MyHeritage hjemsted for verdens bedste AI-teknologier til forbedring og farvelægning af historiske fotos. www.myheritage.dk
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210225005924/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum